Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EMPACT-MI: A Streamlined, Multicentre, Randomised, Parallel Group, Double-blind Placebo-controlled Superiority Trial to Evaluate the Effect of EMPAgliflozin on Hospitalisation for Heart Failure and Mortality in Patients With aCuTe Myocardial Infarction

NCT04509674 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT04509674
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04509674 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EMPACT-MI: A Streamlined, Multicentre, Randomised, Parallel Group, Double-blind Placebo-controlled Superiority Trial to Evaluate the Effect of EMPAgliflozin on Hospitalisation for Heart Failure and Mortality in Patients With aCuTe Myocardial Infarction
Lead sponsor
Boehringer Ingelheim
Phase
Phase 3
Overall status
Completed
Start date
December 16, 2020
Completion date
November 5, 2023
Enrollment
6,522 (actual)
Sites
439

Conditions

As the registry lists them; a condition with its own page is linked.

myocardial infarction